January 29, 2013 In 2013, Incyte Corporation (the makers of Jakafi) in collaboration with CURE Media Group, established a program to honor members of the MPN community. Each honoree can designate an organization to receive $25,000. One of this year’s recipients, Ashley Gould, designated the MPN Research Foundation as the recipient of that prize. Ashley… Read More »MPN HERO DESIGNATES $25,000 FOR RESEARCH
Fatigue is one of the most widely reported symptoms of people living with a myeloproliferative neoplasm. Though common, it is not well understood. A collaborative effort is now underway to 1. help further understanding of the fatigue associated with MPNs and 2. lay the groundworks for the design of a clinical trial to test interventions.… Read More »MPN FATIGUE PROJECT 2013
December 6, 2012 In their ongoing efforts to provide support and resources to the MF community, MPN Research Foundation partner the Cancer Support Community is happy to announce a free webinar Tuesday, December 18th at 3:30 PM EST for those affected by myelofibrosis. This webinar is geared to help patients, caregivers, and others better understand myelofibrosis and… Read More »FRANKLY SPEAKING ABOUT CANCER: MF
September 11, 2012 At the urging of the MPN Research Foundation Illinois Governor Pat Quinn has proclaimed September 20th Myelofibrosis Awareness Day in Illinois! The governor recognized the plight of MF patients who are faced with this rare and progressive blood cancer which can be fatal. Patients, family members and friends will be working hard… Read More »GOVERNOR PAT QUINN PROCLAIMS SEPTEMBER 20TH AS MF DAY IN ILLINOIS
When a patient is diagnosed with myelofibrosis, polycythemia vera, or essential thrombocythemia, it can be an overwhelming and distressing message. Before the advent of the internet it was often difficult to impossible for patients to connect with other individuals who shared their questions and concerns. Today that could not be further from the truth; there… Read More »BLOOD CANCER AWARENSS MONTH: PATIENTS WORKING TOGETHER
Seven Top Hematologists Help Patients Fight Rare Leukemia in a New, Free, On-line Service From MPN ForumJuly 10, 2012 There’s a leukemia so rare – about five cases per one million persons – that chances are you never heard of it or met anyone suffering from it. Most family doctors and even many hematologists have never seen… Read More »MPN CLINIC – BROUGHT TO YOU BY MPN FORUM
(PR)JAKAVI® the first medication to receive Health Canada approval to treat patients with myelofibrosisCanada Newswire (July 5, 2012 8:00 AM) • Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival • PRJAKAVI® (ruxolitinib tablets) approval is based on results from the most extensive… Read More »JAKAVI APPROVED IN CANADA
Effective July 2012, United Health Care now covers Peginterferon Alfa-2a (Pegasys) for treatment of myeloproliferative neoplasms Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (MF). The change in UHC’s coverage policy resulted from a request by the MPN Research Foundation to amend its policy on Pegasys in light of the recent clinical trials showing the significant effectiveness… Read More »UNITED HEALTH CARE APPROVES PEGASYS FOR MPN
Phase 3 Study in Patients with Myelofibrosis and Low Platelet Counts Targetedto Start in Q4-2012 June 4, 2012, Seattle—Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC), announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.’s (“S*BIO”) pacritinib. Pacritinib is a highly selective oral JAK2 (Janus Associated Kinase 2) inhibitor… Read More »CELL THERAPEUTICS COMPLETES ACQUISITION OF PACRITINIB A HIGHLY SELECTIVE JAK2 INHIBITOR
